Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
MWN-AI** Summary
Keros Therapeutics, Inc. (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in therapeutics for disorders related to TGF-ß protein signaling, recently announced its fourth quarter and full year 2025 financial results, alongside notable business highlights. The year 2025 marked a pivotal transition year for Keros, as emphasized by President and CEO, Dr. Jasbir S. Seehra, who noted the company's sharpened strategic focus on executing clinical trials, particularly for rinvatercept, targeting Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).
Recent corporate changes included the addition of Charles Newton to the board of directors and the promotion of Esther Cho to Chief Legal Officer, starting February 2026. Keros anticipates launching a Phase 2 trial of rinvatercept for DMD in Q2 2026 and seeks regulatory guidance for a trial related to ALS within the year.
The financial outcomes for 2025 showcased a significant recovery, reporting a net loss of $23.5 million in Q4 and an overall net income of $87 million for the year, markedly improved from the previous year's losses of $46 million in Q4 and $187.4 million overall. Major contributors to this turnaround included revenue from a licensing agreement with Takeda Pharmaceuticals and a reduction in research and development (R&D) expenses.
Cash reserves dwindled from $559.9 million in 2024 to $287.4 million due to share repurchase activities, yet Keros projects that its cash position will support operations into the first half of 2028. Overall, Keros remains committed to advancing therapeutic solutions while generating long-term value for its shareholders.
MWN-AI** Analysis
Keros Therapeutics’ recent financial results and business updates provide a nuanced view of its trajectory as a clinical-stage biopharmaceutical company. The marked decrease in net losses from $46 million in Q4 2024 to $23.5 million in Q4 2025, alongside significant annual revenue driven by a licensing agreement with Takeda, indicates enhanced operational efficiency and potential for revenue generation moving forward.
The strategic focus on rinvatercept, with advancement into Phase 2 trials for Duchenne muscular dystrophy (DMD) and regulatory engagement for amyotrophic lateral sclerosis (ALS), aligns with industry trends favoring novel therapeutic interventions. This is crucial as the biopharma landscape increasingly prioritizes the development of treatments that target the underlying mechanisms of debilitating diseases.
Keros’ management changes, featuring new board appointments and leadership promotions, may also reflect a recommitment to strategic execution. Leadership stability is especially critical in clinical development phases where regulatory trajectories and trial designs are paramount to success.
However, potential investors should remain cognizant of the risks outlined in the company’s forward-looking statements, which include dependency on ongoing clinical success and funding requirements. The reported cash and cash equivalents of $287 million, while robust, should be closely monitored in relation to burn rates and upcoming trial costs, especially given that the company anticipates funding operational expenses into the first half of 2028.
In conclusion, Keros Therapeutics presents a cautiously optimistic outlook for investors. With a clear focus on pivotal clinical milestones and improved financial metrics, it may be poised for future growth. Nevertheless, attention to potential risks, particularly in clinical development and cash management, will be essential for any investment decision. Investors should stay abreast of Keros' updates leading into 2026, as upcoming trial results could significantly influence market sentiment and stock performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025.
“The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “With that foundation in place, our attention is firmly on execution – advancing rinvatercept into a Phase 2 clinical trial in patients with Duchenne muscular dystrophy (“DMD”) and engaging regulators on the design of a Phase 2 clinical trial in patients with amyotrophic lateral sclerosis (“ALS”). With a strong foundation in place, our focus remains on bringing potential meaningful benefit to patients and creating long-term value for our stockholders.”
Recent Corporate Highlights:
- Board and leadership changes:
- In February 2026, Keros announced the appointment of Charles Newton to its board of directors, effective March 9, 2026. Concurrent with Mr. Newton joining Keros’ Board of Directors, Carl Gordon, Ph.D., C.F.A., will step down as a director of the Company.
- Esther Cho, J.D., Senior Vice President, General Counsel, was promoted to Chief Legal Officer, effective February 24, 2026.
Selected Anticipated Program Milestones:
- Rinvatercept for the treatment of DMD and for the treatment of ALS:
- The Company expects to commence a Phase 2 clinical trial of rinvatercept in patients with DMD in the second quarter of 2026.
- The Company plans to engage regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with ALS in the second half of 2026.
2025 Financial Results
Keros reported a net loss of $23.5 million for the fourth quarter and net income of $87.0 million for the year ended December 31, 2025, as compared to a net loss of $46.0 million for the fourth quarter and a net loss of $187.4 million for the year ended December 31, 2024. The decrease in net loss for the fourth quarter and the net income for the year was largely due to revenue related to Keros’ license agreement with Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), partially offset by research and development efforts as well as additional investments to support the achievement of Keros’ clinical and corporate goals.
Research and development expenses were $17.9 million for the fourth quarter and $129.6 million for the year ended December 31, 2025, as compared to $45.6 million for the fourth quarter and $173.6 million for the year ended December 31, 2024. The decrease in research and development expenses for the fourth quarter and the year was primarily due to the transition of elritercept-related research and development expenses to Takeda.
General and administrative expenses were $11.7 million for the fourth quarter and $46.8 million for the year ended December 31, 2025, as compared to $10.7 million for the fourth quarter and $40.8 million for the year ended December 31, 2024. The increase in general and administrative expenses for the year was primarily due to an increase in external expenses, partially offset by a decrease in compensation costs, including stock-based compensation costs, in connection with a reduction in headcount.
Keros’ cash and cash equivalents as of December 31, 2025 was $287.4 million compared to $559.9 million as of December 31, 2024. The decrease in cash and cash equivalents for the year was primarily driven by Keros’ share repurchase with certain stockholders and cash tender offer. Based on current operating assumptions, Keros expects that its cash and cash equivalents as of December 31, 2025 will enable the Company to fund its planned operating expenses and capital expenditure requirements into the first half of 2028.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including skeletal muscle, bone, adipose, heart tissue and blood. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, rinvatercept, is being developed for the treatment of DMD and for the treatment of ALS. Keros’ most advanced product candidate, elritercept, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “anticipates,” “believes,” “continue,” “expects,” “enable,” “potential” and “will” or similar expressions are intended to identify forward-looking statements. Examples of these forward-looking statements include statements concerning: Keros’ expectations regarding its growth, strategy, progress and the design, objectives and timing of its clinical trials for rinvatercept, including its regulatory plans; and Keros’ expected cash runway. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: Keros’ limited operating history and historical losses; Keros’ ability to raise additional funding to complete the development and any commercialization of its product candidates; Keros’ dependence on the success of its product candidates, rinvatercept and elritercept; that Keros may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Keros’ ability to obtain, maintain and protect its intellectual property; and Keros’ dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.
These and other risks are described more fully in Keros’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Quarterly Report on Form 10-Q, filed with the SEC on November 5, 2025, and its other documents subsequently filed with or furnished to the SEC, including the Company’s Annual Report on Form 10-K as of and for the year ended December 31, 2025. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Keros undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
Media Contact:
Mahmoud Siddig / Adam Pollack / Brooks Hussey
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
| KEROS THERAPEUTICS, INC. Consolidated Statements of Operations (In thousands, except share and per share data) (Unaudited) | ||||||||||||||||
| THREE MONTHS ENDED DECEMBER 31, | YEAR ENDED DECEMBER 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| REVENUE: | ||||||||||||||||
| Service and other revenue | 385 | 42 | 38,706 | 550 | ||||||||||||
| License revenue | — | 3,000 | 205,355 | 3,000 | ||||||||||||
| Total revenue | 385 | 3,042 | 244,061 | 3,550 | ||||||||||||
| OPERATING EXPENSES: | ||||||||||||||||
| Research and development | (17,912 | ) | (45,631 | ) | (129,643 | ) | (173,629 | ) | ||||||||
| General and administrative | (11,743 | ) | (10,665 | ) | (46,849 | ) | (40,754 | ) | ||||||||
| Total operating expenses | (29,655 | ) | (56,296 | ) | (176,492 | ) | (214,383 | ) | ||||||||
| INCOME (LOSS) FROM OPERATIONS | (29,270 | ) | (53,254 | ) | 67,569 | (210,833 | ) | |||||||||
| OTHER INCOME (EXPENSE), NET: | ||||||||||||||||
| Research and development incentive income | — | 1,238 | — | 1,238 | ||||||||||||
| Dividend income | 4,022 | 6,519 | 24,867 | 23,496 | ||||||||||||
| Other income (expense), net | 273 | (229 | ) | (539 | ) | (954 | ) | |||||||||
| Total other income, net | 4,295 | 7,528 | 24,328 | 23,780 | ||||||||||||
| Income (loss) before income taxes | (24,975 | ) | (45,726 | ) | 91,897 | (187,053 | ) | |||||||||
| Income tax provision | 1,514 | (300 | ) | (4,883 | ) | (300 | ) | |||||||||
| Net income (loss) | $ | (23,461 | ) | $ | (46,026 | ) | $ | 87,014 | $ | (187,353 | ) | |||||
| Net income (loss) attributable to common stockholders—basic and diluted | $ | (23,461 | ) | $ | (46,026 | ) | $ | 87,014 | $ | (187,353 | ) | |||||
| Weighted-average common stock outstanding—basic | 27,198,653 | 40,337,720 | 37,221,211 | 37,437,652 | ||||||||||||
| Weighted-average common stock outstanding—diluted | 27,198,653 | 40,337,720 | 37,859,106 | 37,437,652 | ||||||||||||
| Net income (loss) per share of common stock — basic | $ | (0.86 | ) | $ | (1.14 | ) | $ | 2.34 | $ | (5.00 | ) | |||||
| Net income (loss) per share of common stock — diluted | $ | (0.86 | ) | $ | (1.14 | ) | $ | 2.30 | $ | (5.00 | ) | |||||
| KEROS THERAPEUTICS, INC. Consolidated Balance Sheets (In thousands, except share and per share data) (Unaudited) | |||||||
| DECEMBER 31, | |||||||
| 2025 | 2024 | ||||||
| ASSETS | |||||||
| CURRENT ASSETS: | |||||||
| Cash and cash equivalents | $ | 287,415 | $ | 559,931 | |||
| Accounts receivable | 3,567 | 2,742 | |||||
| Prepaid expenses and other current assets | 22,202 | 26,220 | |||||
| Current income tax receivable | 2,250 | — | |||||
| Total current assets | 315,434 | 588,893 | |||||
| Operating lease right-of-use assets | 16,841 | 19,251 | |||||
| Property and equipment, net | 4,297 | 4,237 | |||||
| Restricted cash | 1,449 | 1,449 | |||||
| Other long term assets | — | 2,056 | |||||
| TOTAL ASSETS | $ | 338,021 | $ | 615,886 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| CURRENT LIABILITIES: | |||||||
| Accounts payable | $ | 1,967 | $ | 4,602 | |||
| Current portion of operating lease liabilities | 2,408 | 1,978 | |||||
| Accrued expenses and other current liabilities | 16,039 | 20,870 | |||||
| Total current liabilities | 20,414 | 27,450 | |||||
| Operating lease liabilities, net of current portion | 14,475 | 16,883 | |||||
| Total liabilities | 34,889 | 44,333 | |||||
| COMMITMENTS AND CONTINGENCIES | |||||||
| STOCKHOLDERS’ EQUITY: | |||||||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December 31, 2025 and December 31, 2024; no shares issued and outstanding | — | — | |||||
| Series A junior participating preferred stock, par value of $0.0001 per share; 500,000 and no shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding | — | — | |||||
| Common stock, par value of $0.0001 per share; 200,000,000 authorized as of December 31, 2025 and December 31, 2024; 40,670,466 issued and 19,543,706 outstanding as of December 31, 2025 and 40,554,705 shares issued and outstanding as of December 31, 2024 | 4 | 4 | |||||
| Treasury stock, at cost; 21,126,760 and no shares as of December 31, 2025 and December 31, 2024, respectively | (384,558 | ) | — | ||||
| Additional paid-in capital | 1,169,451 | 1,140,328 | |||||
| Accumulated deficit | (481,765 | ) | (568,779 | ) | |||
| Total stockholders’ equity | 303,132 | 571,553 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 338,021 | $ | 615,886 |
FAQ**
What impact do you anticipate the Phase 2 clinical trials for rinvatercept in Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS) will have on Keros Therapeutics Inc. KROS's long-term growth and stockholder value?
How will the recent leadership changes at Keros Therapeutics Inc. KROS, including the appointment of Charles Newton to the board, influence the company’s strategic direction and operational execution in 2026?
With Keros Therapeutics Inc. KROS reporting a significant decrease in net losses and a net income for 2025, what are your expectations for the company’s financial performance in 2026 and beyond?
Given Keros Therapeutics Inc. KROS's current cash position of $287.4 million, how do you foresee this affecting the company's ability to fund future research and development initiatives amid ongoing clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about Keros Therapeutics Inc. (NASDAQ: KROS).
NASDAQ: KROS
KROS Trading
3.6% G/L:
$11.21 Last:
331,187 Volume:
$10.95 Open:
